Serotonin transporter imaging with [123I]β-CIT SPECT before and after one year of citalopram treatment of obsessive-compulsive disorder

Neuropsychobiology

Volumn 53, Issue 1, 2006, Pages 40-45

  Stengler Wenzke, Katarina ^a   Müller, Ulrich ^a,b   Barthel, Henryk ^a   Angermeyer, Matthias C ^a   Sabri, Osama ^a   Hesse, Swen ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

CIT; Citalopram; Obsessive compulsive disorder; Serotonin transporter; Single photon emission computed tomography

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER I 123; CITALOPRAM; IODINE 123; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN REGION; BRAIN STEM; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MALE; MESENCEPHALON; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSESSIVE COMPULSIVE DISORDER; PILOT STUDY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMUS; TREATMENT DURATION;

ADULT; BRAIN; BRAIN STEM; CITALOPRAM; COCAINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MESENCEPHALON; OBSESSIVE-COMPULSIVE DISORDER; RADIOPHARMACEUTICALS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; THALAMUS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 32844461500     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090702     Document Type: Article

References (33)

1. Kaplan A, Hollander E: A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv 2003;54:1111-1118.
2. Pigott TA, Seay SM: A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999;60:101-106.
3. Dougherty DD, Rauch SL, Jenike MA: Pharmacotherapy for obsessive-compulsive disorder. J Clin Psychol 2004;60:1195-1202.
4. Hand I: Out-patient, multi-modal behaviour therapy for obsessive-compulsive disorder. Br J Psychiatry 1998;35:45-52.
5. Bareggi SR, Bianchi L, Cavallaro R, Gervasoni M, Siliprandi F, Bellodi L: Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results. CNS Drugs 2004;18:329-335.
6. Baxter LR Jr, Thompson JM, Schwartz JM, Guze BH, Phelps ME, Mazziotta JC, Selin CE, Moss L: Trazodone treatment response in obsessive-compulsive disorder correlated with shifts in glucose metabolism in the caudate nuclei. Psychopathology 1987;20:114-122.
7. Benkelfat C, Nordahl TE, Semple WE, King AC, Murphy DL, Cohen RM: Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine. Arch Gen Psychiatry 1990;47:840-848.
8. Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter LR Jr: Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry 2003;160:522-532.
9. Carey PD, Warwick J, Niehaus DJ, van der Linden G, van Heerden BB, Harvey BH, Seedat S, Stein DJ: Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. BMC Psychiatry 2004;4:30.
10. Schwartz JM, Stoessel PW, Baxter LR Jr, Martin KM, Phelps ME: Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1996;53:109-113.
11. Brody AL, Saxena S, Schwartz JM, Stoessel PW, Maidment K, Phelps ME, Baxter LR Jr: FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Res 1998;84:1-6.
12. Rauch SL, Shin LM, Dougherty DD, Alpert NM, Fischman AJ, Jenike MA: Predictors of fluvoxamine response in contamination-related obsessive compulsive disorder: a PET symptom provocation study. Neuropsychopharmacology 2002;27:782-791.
13. Hesse S, Barthel H, Schwarz J, Sabri O, Müller U: Advances in vivo imaging of serotonergic neurons. Neurosci Biobehav Rev 2004;28:547-563.
14. Stengler-Wenzke K, Müller U, Angermeyer MC, Sabri O, Hesse S: Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD). Eur Arch Psychiatry Clin Neurosci 2004;254:252-255.
15. Pirker W, Asenbaum S, Kasper S, Walter H, Angelberger P, Koch G, Pozzera A, Deecke L, Podreka I, Brücke T: beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect 1995;100:247-256.
16. Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, Anand A, Van Dyck CH, Baldwin RM, Seibyl JP, Charney D, Innis RB: Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol Psychiatry 2004;56:497-502.
17. 123I-beta-CIT binding and recovery from depression. A six-month follow-up study. Eur Arch Psychiatry Clin Neurosci 2004;254:152-155.
18. Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F, Ikoma Y, Okubo Y: High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 2003;60:386-391.
19. 11C] DASB. Eur J Nucl Med 2000;27:1719-1722.
20. Meyer JH, Ichise M: Modeling of receptor ligand data in PET and SPECT imaging: a review of major approaches. J Neuroimaging 2001;11:30-39.
21. 11C] DASB positron emission tomography study. Am J Psychiatry 2004;161:826-835.
22. Wittchen HU, Zaudig M, Fydrich T: SKID - strukturiertes klinisches Interview für DSM-IV. Achse I und II: Handanweisungen. Goettingen, Hogrefe, 1997.
23. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Press, 1994.
24. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al: The Yale-Brown Obsessive Compulsive Scale. 1. Development, use and revailibility. Arch Gen Psychiatry 1989;46:1006-1011.
25. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Henninger GR, et al: The Yale-Brown Obsessive Compulsive Scale. 2. Validity. Arch Gen Psychiatry 1989;46:1012-1016.
26. Beck AT, Ward CH, Mendelson J, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:564-571.
27. 123I] β-CIT SPECT and prefrontal cognitive functions in Parkinson's disease. J Neural Transm 2000;107:303-319.
28. Hesse S, Barthel H, Murai T, Müller U, Müller D, Seese A, Kluge R, Sabri O: Is correction for age necessary in neuroimaging studies of the central serotonin transporter? Eur J Nucl Med Mol Imaging 2003;30:427-430.
29. Murai T, Müller U, Werheid K, Sorger D, Reuter M, Becker T, von Cramon DY, Barthel H: In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001;13:222-228.
30. 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med 2000;41:36-44.
31. Mayberg HS: Positron emission tomography imaging in depression: a neural systems perspective. Neuroimaging Clin N Am 2003;13:805-815.
32. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, Frazer A: Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 1999;19:10494-10501.
33. Lesch KP, Wolozin BL, Murphy DL, Reiderer P: Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 1993;60:2319-2322.